Cargando…

Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics

Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is underused in clinical practice. Initial use is delayed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lally, John, Gaughran, Fiona, Timms, Philip, Curran, Sarah R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5106233/
https://www.ncbi.nlm.nih.gov/pubmed/27853387
http://dx.doi.org/10.2147/PGPM.S115741